# S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

Study · id `cardio:ct-nct03226340` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03226340](<https://clinicaltrials.gov/study/NCT03226340>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03226340

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.

## Technical summary

Registry record NCT03226340. Randomized; no masking; primary purpose treatment. Start 2015-12-02 (actual); primary completion 2018-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 170 participants (planned count; ClinicalTrials.gov record NCT03226340, source copy `cardio:ctgov-nct03226340-2017-07-21`, retrieved 2026-10-26)
- Started: 2015-12-02 (actual) (ClinicalTrials.gov record NCT03226340, source copy `cardio:ctgov-nct03226340-2017-07-21`, retrieved 2026-10-26)
- Primary completion: 2018-03-31 (anticipated) (ClinicalTrials.gov record NCT03226340, source copy `cardio:ctgov-nct03226340-2017-07-21`, retrieved 2026-10-26)
- Completion: 2018-03-31 (anticipated) (ClinicalTrials.gov record NCT03226340, source copy `cardio:ctgov-nct03226340-2017-07-21`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03226340, source copy `cardio:ctgov-nct03226340-2017-07-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03226340-2017-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): S-amlodipine 2.5mg + Chlorthalidone 25mg
- Intervention (Drug): S-amlodipine 2.5mg + Telmisartan 40mg
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER
- Collaborator: Hanlim Pharm. Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)
- Registry lists this organization as a collaborator: Hanlim Pharm. Co., Ltd. (`cardio:org-hanlim-pharm-co-ltd`)

## Provenance

Content hash: ba52eaf3c1f3eeb3cb1cb492642cce503856ae7d658dad32351dbfa5f9ff9887
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
